№ lp_1_09902
File format: docx
Character count: 4682
File size: 94 KB
Year:
2026
Region / City:
Missouri
Topic:
Hereditary Angioedema Treatment
Document Type:
Proposal
Institution:
MO HealthNet
Author:
MO HealthNet and Conduent
Target Audience:
Health professionals and stakeholders in the MO HealthNet program
Effective Period:
Starting from May 9, 2019
Approval Date:
January 20, 2026
Modification Date:
Not specified
Document Status:
Revision of Existing Criteria
Context:
A proposal outlining the preferred drug list and approval criteria for hereditary angioedema treatment agents within the MO HealthNet program.
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Document type:
Press release
Topic:
Rare diseases; hereditary angioedema
Event:
hae day :-)
Date:
16 May
Geographic scope:
Global
Organizing body:
HAE International (HAEi)
Organizational type:
Global non-profit network of patient associations
Target audiences:
General public; healthcare professionals; healthcare decision-makers; industry representatives
Key activity:
Global physical and wellbeing activities converted into steps
Campaign theme:
#active4HAE in purple
Campaign period:
Early April to end of May
Medical condition described:
Hereditary angioedema
Risks described:
Potential fatal airway swelling
Supporting organizations:
National HAE patient organizations
Primary spokesperson cited:
President of HAE International
Online platform referenced:
haeday.org
Press material section:
Notes to editors; About hae day :-); About HAEi
Source type:
Organizational public communication announcing a global health awareness campaign coordinated by an international patient advocacy network and describing planned activities, medical background, and participation framework.
Country:
United Kingdom
Topic:
Hereditary angioedema and acquired C1 inhibitor deficiency
Document type:
Medical research article
Study type:
National survey
Authors:
Patrick FK Yong; Tanya Coulter; Tariq El-Shanwany; Tomaz Garcez; Scott Hackett; Rashmi Jain; Sorena Kiani-Alikhan; Ania Manson; Sadia Noorani; Catherine Stroud; Christine Symons; Ravishankar Sargur; Cathal Steele; Hana Alachkar; Ariharan Anantharachagan; Peter D Arkwright; Jolanta Bernatoniene; Malini Bhole; Lindsay Brown; Matthew Buckland; Siobhan Burns; Charu Chopra; James Darroch; Elizabeth Drewe; Jillian Edmonds; Anjali Ekbote; Shuayb Elkhalifa; Sarah Goddard; Dorothea Grosse-Kreul; Padmalal Gurugama; Rosie Hague; Richard Herriot; Archana Herwadkar; Stephen M Hughes; Laura Jones; Sara Lear; Elizabeth McDermott; Sai Hurng Kham Murng; Arthur Price; Vyanka Redenbaugh; Alex Richter; Andrew Riordan; Fiona Shackley; Julia Stichbury; Debbie Springett; Michael D Tarzi; Moira Thomas; Pavaladurai Vijayadurai; Austen Worth
Institutions:
Multiple NHS trusts and university hospitals across England, Scotland, Wales, and Northern Ireland
Corresponding author:
Patrick FK Yong
Corresponding institution:
Frimley Health NHS Foundation Trust
Methodology:
Questionnaire survey of specialist centres managing hereditary angioedema and acquired C1 inhibitor deficiency
Number of participating centres:
37
Patient population:
Individuals with HAE-1/2, HAE with normal C1 inhibitor, and acquired C1 inhibitor deficiency
Sample size:
1265 patients
Medical conditions studied:
Hereditary angioedema; acquired C1 inhibitor deficiency
Key treatments mentioned:
Danazol; C1 inhibitor replacement therapy; icatibant; tranexamic acid
Funding source:
Unrestricted grant from Pharming
Keywords:
hereditary angioedema; acquired C1 inhibitor deficiency; epidemiology; demographics; treatment modalities; United Kingdom
Year:
2026
Region / City:
United States
Topic:
Antiretroviral Therapy (ART)
Document Type:
Proposal
Institution:
MO HealthNet
Author:
MO HealthNet, Conduent
Target Audience:
Healthcare professionals, policymakers, and health program administrators
Effective Period:
2026–
Approval Date:
January 20, 2026
Revision Date:
April 7, 2022
Year:
2026
Region / City:
Missouri, USA
Topic:
Neuropathic Pain Agents
Document Type:
Proposal
Institution:
MO HealthNet
Author:
MO HealthNet and Conduent
Target Audience:
Healthcare providers and MO HealthNet participants
Approval Period:
1 year
Approval Date:
January 20, 2026
Revision Date:
May 29, 2013
Year:
2026
Region / City:
MO HealthNet
Topic:
Dravet Syndrome, Anticonvulsants
Document Type:
Proposal
Organization:
MO HealthNet
Author:
MO HealthNet and Conduent
Target Audience:
Healthcare providers, MO HealthNet participants
Effective Period:
Ongoing
Approval Date:
January 20, 2026
Amendment Date:
N/A
Year:
2026
Region / City:
United States
Topic:
Antiretroviral Therapy (ART)
Document Type:
Proposal
Institution:
MO HealthNet
Author:
MO HealthNet, Conduent
Target Audience:
Healthcare professionals, policymakers, and health program administrators
Effective Period:
2026–
Approval Date:
January 20, 2026
Revision Date:
April 7, 2022
Year:
2026
Region / City:
MO HealthNet
Theme:
NSAIDs, Pharmacology, Health Policy
Document Type:
Proposal
Institution:
MO HealthNet, Conduent
Author:
MO HealthNet and Conduent
Target Audience:
Healthcare Providers, Policy Makers, MO HealthNet Participants
Period of Validity:
Indefinite
Approval Date:
January 20, 2026
Modification Date:
None
Year:
2026
Region / City:
Missouri, USA
Topic:
Neuropathic Pain Agents
Document Type:
Proposal
Institution:
MO HealthNet
Author:
MO HealthNet and Conduent
Target Audience:
Healthcare providers and MO HealthNet participants
Approval Period:
1 year
Approval Date:
January 20, 2026
Revision Date:
May 29, 2013
Year:
2026
Region / City:
MO HealthNet
Topic:
Dravet Syndrome, Anticonvulsants
Document Type:
Proposal
Organization:
MO HealthNet
Author:
MO HealthNet and Conduent
Target Audience:
Healthcare providers, MO HealthNet participants
Effective Period:
Ongoing
Approval Date:
January 20, 2026
Amendment Date:
N/A
Year:
2026
Region / City:
Missouri
Theme:
Fibromyalgia Treatment
Document Type:
Medical Criteria Proposal
Author:
MO HealthNet and Conduent
Target Audience:
MO HealthNet participants, healthcare providers
Approval Date:
January 20, 2026
Period of Validity:
Not specified
Change Date:
Not specified
Year:
2026
Region / city:
Missouri
Document Type:
Proposal
Organization:
MO HealthNet
Author:
MO HealthNet, Conduent
Target Audience:
MO HealthNet participants, healthcare providers
Period of validity:
Ongoing
Approval Date:
January 20, 2026
Revision Date:
May 21, 2008
Criteria Status:
Revision of Existing Criteria